Advances in Cancer Immunotherapy™ (ACI™-OR)

Purpose

Specifically designed for clinical oncologists and the entire unit of care involved in treating cancer patients with immunotherapy, these introductory, CME-certified programs will provide an understanding of basic immunology principles in the clinical application and management of cancer immunotherapy and discuss emerging drugs and concepts in the cancer immunotherapy field.

Presented by leading authorities in tumor immunology and cancer immunotherapy, these programs will facilitate understanding of 1) the underlying principles of tumor immunology and immunotherapy, 2) the clinical indications for cancer immunotherapy and appropriate selection of patients, 3) patient management, and 4) the therapeutic effectiveness of immunotherapy to ultimately improve patient outcomes.

Attendees can also take advantage of the opportunity for professional networking that will promote collaboration and scientific exchange with experts, clinical oncologists and other health care providers from the surrounding community.
Intended Audience

The target audience for these programs includes clinical oncologists, those involved in patient care, early career individuals, allied health professionals, and patient advocates who wish to learn principles of tumor immunology and immunotherapy, as well as improve their ability to select patients for immunotherapy and provide state-of-the-art clinical management for their patients.

Session Topics

Biomarkers: How to Select the Correct Patient for Which Therapy
Cell Therapy
Combination Therapy
Current State of Immune Checkpoint Inhibitors
Immune Changes Associated with Tumor Growth and Regression
Immunology 101
Inflammation and Tumor Development
Oncolytic Virus Therapy in Cancer Immunotherapy
Radiation and Immune Therapy

Educational Objectives

Upon completion of this program, the participants will be able to:

-Interpret the key principles of tumor immunology and immunotherapy
-Analyze recent research and clinical applications of cytokines, cancer vaccines, T cell checkpoint inhibitors, adoptive immunotherapy and biomarkers
-Participate in scientific exchange with local colleagues, potential collaborators, and subject matter experts on research and clinical application of cancer immunotherapy
-Implement cancer immunotherapy treatments into clinical practice more effectively through a sound understanding of how they work, the clinical management of patients, and the potential to improve patient outcomes with tumor immunotherapy

+ show speakers and program
Program Schedule

(as of June 26, 2014)

Presentations include allotted time for Audience Response System (ARS) assisted audience interaction as well as general question and answer time.

8:00 am - 8:10 am Welcome and Overview

Session I: Basic Principles of Tumor Immunology and Immunotherapy with AMA PRA Category 1 Credits™

8:10 am - 9:05 am Immunology 101
Amy E. Moran, PhD – Earle A. Chiles Research Institute, Providence Cancer Center

9:05 am - 9:35 am Regulation of the Immune Response
Michael J. Gough, PhD – Earle A. Chiles Research Institute, Providence Cancer Center

9:35 am - 10:05 am Principles of Immunotherapy
Bernard A. Fox, PhD – Earle A. Chiles Research Institute, Providence Cancer Center

10:05 am - 10:20 am Panel Discussion

10:20 am - 10:35 am Break

Session II: Checkpoint Blockade-Based Immunotherapy with AMA PRA Category 1 Credits™

10:35 am - 11:05 am CTLA-4 Blockade: Indications and Clinical Management
Walter J. Urba, MD, PhD – Earle A. Chiles Research Institute, Providence Cancer Center

11:05 am - 11:35 am Blockade of the PD-1/PDL-1 Axis Inhibition
Omid Hamid, MD - The Angeles Clinic and Research Institute

11:35 am - 12:05 pm Combinations and Other Immune Checkpoint Inhibitors/Agonists
Brendan D. Curti, MD – Earle A. Chiles Research Institute, Providence Cancer Center

12:05 pm - 12:25 pm Radiation and Immunotherapy
Marka R. Crittenden, MD, PhD – Earle A. Chiles Research Institute, Providence Cancer Center

12:25 pm - 12:45 pm Panel Discussion

12:45 pm - 1:30 pm Lunch

Session III: Non-Checkpoint Blockade-Based Immunotherapy with AMA PRA Category 1 Credits™

1:30 pm - 2:00 pm Cytokines (IL-2 and IFN): Indications and Clinical Management
Brendan D. Curti, MD – Earle A. Chiles Research Institute, Providence Cancer Center

2:00 pm - 2:30 pm Adoptive T Cell Therapy with Variations
Mark Faries, MD – The John Wayne Cancer Institute

2:30 pm - 3:00 pm Vaccines
Keith S. Bahjat, PhD – Earle A. Chiles Research Institute, Providence Cancer Center

3:00 pm - 3:20 pm Panel Discussion

3:20 pm - 3:30 pm Closing Remarks

3 Oct - 3 Oct 2014
Portland
United States of America
meeting website